These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9372064)
21. Pathogenesis and treatment of sickle cell disease. Bunn HF N Engl J Med; 1997 Sep; 337(11):762-9. PubMed ID: 9287233 [No Abstract] [Full Text] [Related]
22. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels. Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995 [No Abstract] [Full Text] [Related]
23. Optimizing hydroxyurea therapy for sickle cell anemia. Ware RE Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755 [TBL] [Abstract][Full Text] [Related]
24. Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients. Teixeira SM; Cortellazzi LC; Grotto HZ Braz J Med Biol Res; 2003 Oct; 36(10):1289-92. PubMed ID: 14502358 [TBL] [Abstract][Full Text] [Related]
25. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Selby R; Nisbet-Brown E; Basran RK; Chang L; Olivieri NF Blood; 1997 Jul; 90(2):891-3. PubMed ID: 9226193 [No Abstract] [Full Text] [Related]
26. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131 [TBL] [Abstract][Full Text] [Related]
32. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965 [TBL] [Abstract][Full Text] [Related]
33. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Anderson N Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291 [TBL] [Abstract][Full Text] [Related]
34. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea. Dover GJ Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530 [TBL] [Abstract][Full Text] [Related]
35. Atrial septal defect closure on cardiopulmonary bypass in a sickle cell anemia: role of hydroxyurea and partial exchange transfusion. Gosavi KS; Dash SK; Shah BN; Upasani CB Ann Card Anaesth; 2010; 13(2):145-7. PubMed ID: 20442545 [TBL] [Abstract][Full Text] [Related]
36. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease. Cui S; Engel JD Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681 [TBL] [Abstract][Full Text] [Related]
38. Hydroxyurea for sickle cell anemia. Naina HV; Harris S N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283 [No Abstract] [Full Text] [Related]
39. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. Brugnara C; Gee B; Armsby CC; Kurth S; Sakamoto M; Rifai N; Alper SL; Platt OS J Clin Invest; 1996 Mar; 97(5):1227-34. PubMed ID: 8636434 [TBL] [Abstract][Full Text] [Related]
40. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Kassim AA; DeBaun MR Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]